44 Organisations

Venture Capital

Venture capital firms — both generalist and psychedelic-native funds — investing in psychedelic biotech and services companies.

Organisations: 44
Countries: 7

Investor Finder

Company Context

Showing 44 of 44

Able Partners
Able Partners is a New York City-based venture capital firm focused on early-stage consumer companies in health and wellness, with a stated emphasis on improving everyday life and wellbeing. The firm’s team page describes its partners as active investors in early-stage consumer and healthcare businesses, and its public materials frame the firm’s thesis around “positive living” and closing the wellness gap. In the psychedelic ecosystem, Able Partners is relevant because its public portfolio and investment themes include mental health, substance-use treatment, and companies building around psychedelic-adjacent care delivery. Its website also shows involvement with atai Life Sciences and Compass Pathways, suggesting exposure to the psychedelic mental-health stack alongside broader healthcare and consumer wellness bets.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Company-Led Drug Development & CommercializationEducational Platforms & Resources
Portfolio Signals
COMPASS Pathways
Series B · undisclosed · Jan 1, 2020
Aja Ventures
Aja Ventures is a Canadian investment company associated with venture investing in plant medicine, technology, and wellness, with a stated emphasis on early-stage ventures developing psychedelic medicine. Public-facing profiles also describe it as a venture capital fund or investment company connected to psychedelic-adjacent healthcare and longevity themes. It matters in the psychedelic ecosystem because its stated strategy includes backing early-stage psychedelic therapy and drug-discovery efforts, alongside related areas like genetic testing, functional medicine, and personalized healthcare. Public profile sources also point to investments or strategic exposure in companies tied to natural psychedelic medicines and plant-based wellness.
View Profile
Investor Category
Venture Capital
HQ
HQ: Canada
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
Filament Ventures
Cellular Goods
Seed · undisclosed · Mar 1, 2021
Ambria Capital
Ambria Capital is a venture capital firm that focuses on early-stage companies in mental health and technology, with a stated current emphasis on psychedelic therapies and technologies. The firm says it invests its own money and can fund companies at any stage and in any amount, and its leadership includes founder Michael Sobeck and managing partner Cody Shandraw. The firm matters in the psychedelic ecosystem because it explicitly backs psychedelic therapies and technologies and describes itself as one of the more active investors in the space. Its website and related public materials point to investments and support across the industry, including companies such as Wesana Health, and it has also been associated with broader neurowellness and brain-health investing through Phyto Partners.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
Public portfolio context is limited.
Apeiron Investment Group
Apeiron Investment Group is a discretionary investment firm founded and owned by Christian Angermayer. Its website says it manages approximately $7 billion and operates with teams in New York, London, Berlin, Abu Dhabi, and Malta, with a primary focus on the U.S. market. It matters in the psychedelic ecosystem because Apeiron has been a recurring backer of atai Life Sciences, including co-leading atai's $125 million Series C financing in 2020 and its $50 million private placement financing in 2025. Apeiron's own website also describes psychedelics as a key part of its investment story and says it has been instrumental in the renaissance of psychedelics as treatments for mental health issues.
View Profile
Investor Category
Venture Capital
HQ
HQ: United Arab Emirates
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
atai Life Sciences
Private placement financing (co-led) · $50m financing · Jul 1, 2025
Apollo Projects
Apollo Projects is a venture platform associated with moonshot-style company building and early investments. Public sources describe it as a vehicle launched by the Altman brothers in 2020, with a broad mandate rather than a psychedelic-specific strategy. Its relevance to psychedelic medicine comes from Journey Colab, where Apollo Projects appears in launch and Series A financing evidence. The record should be treated as moderate-confidence broad venture capital with a verified Journey Colab connection.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
Pre-SeedSeedSeries A/B
Company-Led Drug Development & Commercialization
Portfolio Signals
Journey Colab
Initial investment · $3 million · Oct 26, 2020
ARTIS Ventures
ARTIS Ventures is a San Francisco venture capital firm focused on frontier technologies at the intersection of life science, health, and advanced computing. Its current public language emphasizes resilience, TechBio, and backing companies that reshape human health and related systems. ARTIS is a strong psychedelic-adjacent investor record because it has direct exposure to Delix Therapeutics and publicly hosts Delix within its portfolio. It should be described as a techbio and healthcare VC with a source-backed neuroplastogen investment, not as a dedicated psychedelic investor.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/B
Company-Led Drug Development & Commercialization
Portfolio Signals
Delix Therapeutics
Series A · $70 million · Sep 27, 2021
Blackhawk Growth Corp
Blackhawk Growth Corp. is a publicly traded Canadian investment holding company / investment issuer that invests in equity and debt instruments of companies to generate shareholder returns. Public filings and exchange listings place the company in Vancouver, British Columbia, Canada, while the company itself has also described its strategy as active support for portfolio companies in North America. It matters in the psychedelic ecosystem because Blackhawk has publicly backed psychedelic-related drug development, including MindBio Therapeutics, which it described as a clinical-stage company pioneering psychedelic microdosing research. That makes Blackhawk a relevant crossover investor in the adjacent cannabis, mental health, and psychedelic therapeutics landscape rather than a pure-play life sciences fund.
View Profile
Investor Category
Venture Capital
HQ
HQ: Canada
SeedSeries A/BGrowth / Late StageNonprofit / grant-backed
Company-Led Drug Development & Commercialization
Portfolio Signals
MindBio Therapeutics
private investment · Aug 31, 2021
Boxer Capital
Boxer Capital is a biotechnology investment firm and private investment fund based in San Diego, California. Its public materials describe it as a full life cycle investor focused on fundamental, research-based investing across private and public markets, with activity spanning early-stage through late-stage biotech. It matters to the psychedelic ecosystem because its investing style overlaps with the kinds of capital needed by drug-development companies, including crossover, private, and public-market financing. Boxer Capital’s public disclosures emphasize investing across the drug development lifecycle and supporting therapeutics companies from company formation through late-stage development, which can make it relevant to psychedelic medicine companies even when they are not explicitly psychedelic-focused.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Company-Led Drug Development & CommercializationEducational Platforms & Resources
Portfolio Signals
GH Research
Series B · undisclosed · Apr 1, 2021
Cybin
registered direct offering · undisclosed · Jun 1, 2025
BVF Partners
BVF Partners L.P. is a private investment manager based in San Francisco, California. Public filings and market data describe it as an SEC-registered investment adviser and biotechnology-focused investor, rather than a broad consumer or software venture fund. In the psychedelic ecosystem, BVF Partners matters mainly as a healthcare and drug-development capital provider whose investment style aligns more with life sciences than with lifestyle psychedelics. Publicly available sources point to biotech as its core theme, which makes it potentially relevant to companies developing regulated therapeutic compounds and clinical-stage programs.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
Public portfolio context is limited.
Catalio Capital Management
Catalio Capital Management is a New York-based healthcare investment firm that invests across private, public, and credit markets. Its public materials emphasize innovative healthcare companies across the company lifecycle, with a strong orientation toward biomedical technology. Catalio belongs in the psychedelic ecosystem as a healthcare-specialist investor with atai-related investments and a historical COMPASS Pathways connection through Camden Partners Nexus. It should be read as a life-science investor with repeated source-backed sector exposure, not as a dedicated psychedelic fund.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
Multi-Stage
Company-Led Drug Development & CommercializationEducational Platforms & Resources
Portfolio Signals
atai Life Sciences
Series C · $125 million · Nov 23, 2020
COMPASS Pathways
Series B · $80m · Apr 27, 2020
Deerfield
Deerfield Management Company is a healthcare investment firm launched in 1994. Its public materials describe it as an investor across therapeutics, medical devices, diagnostics, digital health, and healthcare services, investing across the capital structure and at all stages of company development. Deerfield’s contact page lists its New York City office at 345 Park Avenue South in New York, New York, United States. Deerfield is relevant to the psychedelic ecosystem primarily through its broad therapeutics focus and its ability to back early-stage to later-stage life science companies. While its public website does not identify a dedicated psychedelic program, its investment platform includes drug-development-oriented work and a portfolio spanning early-stage therapeutics, which makes it a plausible investor in adjacent mental-health and neurotherapeutics opportunities.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
Public portfolio context is limited.
Empath Ventures
Empath Ventures is a venture capital firm focused on psychedelic medicine and related therapeutic approaches. Public profiles place the firm in Los Angeles, California, United States, and describe it as an early-stage investor with activity across seed and Series A stages, with some sources also indicating broader stage coverage. The firm is relevant to the psychedelic ecosystem because it has publicly positioned itself around psychedelic medicine companies and adjacent health technologies. Public references also connect Empath Ventures to companies and themes in psychedelic medicine, neurotechnology, and novel therapeutics.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Media & CommunicationTechnology, Data, & Software Platforms
Portfolio Signals
Wavepaths
Seed · $4.5M · Nov 1, 2021
Evolve Ventures
Evolve Ventures is the venture arm of EVOLVE, an umbrella organization that says it has two divisions: Evolve Ventures and Evolve Foundation. The firm says Evolve Ventures was initially funded by the Shao family with a $100 million pool and invests in for-profit companies aligned with its mission. The organization describes its work as global, with a particular focus on the United States and China. Evolve Ventures appears in the psychedelic ecosystem through its investments in companies such as Beckley Waves, Homecoming, and MycoMedica on its public investments page. Its portfolio also includes mental health, meditation, and consciousness-oriented companies, which places it near the broader psychedelic-adjacent landscape even when the company itself is not a direct drug-developer.
View Profile
Investor Category
Venture Capital
HQ
Not listed
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
Beckley Waves
program-related investment
Homecoming
venture investment
Founders Fund
Founders Fund is a generalist venture capital firm known for backing large, category-defining technology companies across sectors. Its public positioning is broad rather than healthcare-specific, and the firm is not publicly organized around psychedelic medicine. Its relevance to psychedelic medicine comes from participation in COMPASS Pathways' 2020 Series B round. That makes Founders Fund a meaningful crossover investor in a landmark psilocybin drug developer, but not a dedicated psychedelic investor.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
Multi-Stage
Company-Led Drug Development & CommercializationEducational Platforms & Resources
Portfolio Signals
COMPASS Pathways
Series B · $80m · Apr 27, 2020
Future Ventures
Future Ventures is a venture capital firm co-founded by Steve Jurvetson and Maryanna Saenko. The firm says it focuses on seed and early-stage investments in founder-led, mission-driven companies and describes itself as based in Pacifica, California through Saenko’s public bio and the firm’s Bay Area footprint. Future Ventures matters in the psychedelic ecosystem because it has backed and publicly listed atai Life Sciences and Osmind, both adjacent to mental health and psychedelic medicine infrastructure. Its public materials also emphasize biology, therapeutics, and frontier technology, which aligns with the broader ecosystem around drug development and digital care platforms.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
atai Life Sciences
private investment
Hercules Capital
Hercules Capital, Inc. is a publicly traded specialty finance company and business development company focused on senior secured venture growth loans for venture capital-backed companies. It was founded in 2003 and is based in San Mateo, California, in the United States. Hercules is relevant to the psychedelic ecosystem because its life sciences practice finances biotechnology and other healthcare companies at clinical and commercial stages, including companies in the broader CNS and drug development space. Public filings show Hercules has been a lender to ATAI Life Sciences, making it a financing counterpart to a psychedelics-focused public company.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late StageNonprofit / grant-backed
Portfolio Signals
atai Life Sciences
private placement · Jan 1, 2025
Iter Investments
Iter Investments is a venture capital firm focused on emerging companies developing alternative therapeutics for behavioral and mental health, with a stated emphasis on the psychedelic ecosystem. The firm’s public materials describe it as a Florida-based investor, with headquarters in South Florida. Iter matters in the psychedelic ecosystem because it backs companies across the sector’s value chain, including drug development, clinics, digital platforms, and supporting infrastructure. Its public portfolio includes Psygen, Awakn Life Sciences, Wesana, PsyTech, and Nucleus-related ecosystem assets, showing a broad strategy beyond a single therapeutic modality.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
Pre-SeedSeedSeries A/B
Company-Led Drug Development & CommercializationPharmaceutical Manufacturing
Portfolio Signals
Psygen
Portfolio investment
Awakn Life Sciences
Portfolio investment
JLS Fund
JLS Fund is a venture capital fund focused on neuroscience and psychedelic medicine. Its website says the firm was founded in 2019 and lists a New York office at 40 Sutton Place, New York, USA. The fund is active across the psychedelic ecosystem through investments and advisories in companies such as Enthea, Psilera, TRIPP, Gilgamesh, and ProNovo Therapeutics. It also publishes regular industry commentary on psychedelics and neuroscience, which helps position it as a visible specialist investor in the sector.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Company-Led Drug Development & Commercialization
Portfolio Signals
Enthea
Fund investment
Psilera
Fund investment
Leafy Tunnel
Leafy Tunnel is a venture capital firm focused on alternative medicine, with an emphasis on medicinal cannabis and psychedelics. Its public-facing materials describe it as an early-stage investor and place its headquarters in London, United Kingdom. In the psychedelic ecosystem, Leafy Tunnel matters because it has publicly positioned itself around medical cannabis and global medical psychedelics opportunities, with a stated focus on Seed and Series A investing. Public funding coverage shows it led Lyphe Group’s £5m Series A round in 2022, supporting expansion across Europe.
View Profile
Investor Category
Venture Capital
HQ
HQ: United Kingdom
SeedSeries A/BGrowth / Late StageNonprofit / grant-backed
Portfolio Signals
Public portfolio context is limited.
Levitee Labs
Levitee Labs Inc. is a British Columbia company that was incorporated on January 23, 2019 and later became listed on the Canadian Securities Exchange under the symbol LVT. Public filings describe it as an integrative wellness company with activities aimed at alternative medicine and the broader psychedelic industry. The company’s public disclosures frame its role around acquiring and building wellness assets complementary to the evolving psychedelic sector, including clinics, pharmacies, nutraceuticals, and other adjacent healthcare businesses. That makes Levitee Labs relevant as an operator and capital allocator around psychedelic-adjacent healthcare infrastructure rather than a traditional early-stage venture fund.
View Profile
Investor Category
Venture Capital
HQ
HQ: Canada
SeedSeries A/BGrowth / Late Stage
Clinical Care Delivery Organizations
Portfolio Signals
Public portfolio context is limited.
MBX Capital
MBX Capital is an early-stage venture capital firm focused on deep health companies, with an official FAQ stating it is agnostic to sector so long as the company has a clear deep health vision. The firm says it typically invests in companies’ first or second institutional rounds and can also participate in later-stage financings. Its public mailing address is in Claymont, Delaware, United States. In the psychedelic ecosystem, MBX Capital is relevant because its portfolio page includes Journey Colab, described as building psychedelic therapies for addiction, alongside other mental-health and neuro-related companies. That makes MBX Capital a broader deep-health investor with at least one public psychedelic-adjacent portfolio company and a stated willingness to invest globally when the opportunity fits.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Company-Led Drug Development & Commercialization
Portfolio Signals
Journey Colab
Partnered · Jan 1, 2021
Negev Capital
Negev Capital is a venture capital fund focused on CNS and brain-health therapeutics, with a stated strategy centered on seed to Series A investments. The fund says it is domiciled in the Cayman Islands and that key team members are based in Limassol, Cyprus, Vienna, and New York. It matters in the psychedelic ecosystem because Negev Capital has backed and exited multiple companies in psychedelic-derived and neuropsychiatric drug development, including Gilgamesh Pharmaceuticals, Mindset Pharma, Bright Minds Biosciences, and others. The fund describes its thesis as supporting psychedelic-derived and novel neuropsychiatric compounds that can mature into mainstream therapeutic categories.
View Profile
Investor Category
Venture Capital
HQ
HQ: Cayman Islands
SeedSeries A/BGrowth / Late Stage
Academic & Non-Profit Research
Portfolio Signals
Small Pharma Ltd
follow-on / strategic investment · USD 1 million cumulative · Sep 21, 2021
Neo Kuma
Neo Kuma Ventures LLP is a London-based venture capital investor focused on psychedelic healthcare and adjacent drug-development opportunities. Public materials describe it as investing in early-stage psychedelic healthcare companies, with a global market scope and a European tilt. The firm is relevant to the psychedelic ecosystem because it has backed several of the sector’s best-known companies and positions itself around clinical research, therapeutics, and regulated healthcare delivery. Public profiles and coverage identify portfolio exposure to companies such as Atai Life Sciences, Beckley Psytech, and Bright Minds Biosciences.
View Profile
Investor Category
Venture Capital
HQ
HQ: United Kingdom
SeedSeries A/BGrowth / Late Stage
Company-Led Drug Development & Commercialization
Portfolio Signals
atai Life Sciences
Series C · undisclosed · Nov 1, 2020
Bright Minds Biosciences
undisclosed
OMX Venture
OMX Ventures is a venture capital firm based in Chicago, Illinois, focused on bioengineering and life sciences investing. Its public materials describe a technology-first approach centered on early-stage companies working across biology, big data, AI, therapeutics, bio tools, diagnostics, and synthetic biology. In the psychedelic ecosystem, OMX matters because it is a founding investor in Delix Therapeutics, a company developing non-hallucinogenic versions of psychedelic compounds for psychiatric and neurological indications. OMX has also publicly participated in other drug-development and biotech rounds, suggesting a broader interest in therapeutics that overlap with psychedelic-adjacent neuroscience.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Company-Led Drug Development & Commercialization
Portfolio Signals
Delix Therapeutics
Series A · $70 million · Sep 27, 2021
Origin Therapeutics
Origin Therapeutics Holdings Inc. is a publicly listed, actively managed investment issuer focused on equity investments in psychedelics-related companies. Public company materials place it in Vancouver, British Columbia, which strongly suggests a Canadian base. The firm is positioned as a sector investor rather than an operating biotech, with a mandate to provide investors diversified exposure to private psychedelics companies. Its public materials and announcements show an emphasis on early-stage and growth-oriented psychedelic businesses, especially drug development. Origin Therapeutics appears to function as a specialized capital provider in the psychedelic ecosystem, with portfolio updates centered on companies developing psilocybin-based therapies. That makes it relevant as a financing vehicle and visibility source for emerging psychedelic drug programs.
View Profile
Investor Category
Venture Capital
HQ
HQ: Canada
SeedSeries A/BGrowth / Late StageNonprofit / grant-backed
Company-Led Drug Development & Commercialization
Portfolio Signals
Xpira Pharmaceuticals
Sep 22, 2022
Clairvoyant Therapeutics
Jul 7, 2022
Oscillate
Oscillate PLC is a publicly listed investment company on the Aquis Stock Exchange Growth Market. Its public corporate filings show it is incorporated in England and Wales, with a registered office in London, United Kingdom. Oscillate became relevant to the psychedelic ecosystem after broadening its investment strategy in 2021 to cover medical psychedelics. Public company materials indicate it has held an investment portfolio that included psychedelic-sector opportunities and that the company has been focused on early-stage companies in the space.
View Profile
Investor Category
Venture Capital
HQ
HQ: United Kingdom
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
Public portfolio context is limited.
Palo Santo
Palo Santo is a venture capital fund focused on neuroscience and mental health innovation, with an explicit emphasis on next-generation psychedelic therapeutics and enabling technologies. Its public materials describe the firm as investing across novel CNS therapeutics, digital and clinical technologies, and related brain-health infrastructure. The firm is notable in the psychedelic ecosystem because its portfolio includes multiple companies working on psychedelic medicines, serotonergic agonists, ketamine-assisted care, and related CNS drug discovery. Palo Santo also highlights portfolio outcomes such as pharma acquisitions and FDA breakthrough designations across its neuroscience and psychedelic focus areas.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Company-Led Drug Development & CommercializationEducational Platforms & ResourcesPractitioner-Led Care Organizations
Portfolio Signals
Gilgamesh Pharma
undisclosed
Transcend Therapeutics
undisclosed
Phyto Partners
Phyto Partners is a venture capital firm based in Boca Raton, Florida. Its public materials describe the firm as investing in businesses around cannabis and, more recently, a psychedelic-focused fund called Phyto Psyche. In the psychedelic ecosystem, Phyto Partners matters as one of the earlier cannabis-to-psychedelics crossover investors, with public materials describing an investment thesis around brain health, neurowellness, and psychedelic therapeutics. The firm’s psychedelic content emphasizes a focus on privately held companies and drug-development-oriented opportunities.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
Public portfolio context is limited.
Presight Capital
Presight Capital is a venture capital fund associated with Christian Angermayer and Apeiron Investment Group. It invests across sectors and stages, with public descriptions indicating a seed-to-growth orientation and a global remit. A public address on the firm’s website places it in West Hollywood, California, United States. Presight matters in the psychedelic ecosystem because it has appeared in the investor syndicate of Delix Therapeutics, a preclinical neuroscience company developing non-hallucinogenic analogs of psychedelics. Public reporting also links Presight to Compass Pathways, making it a visible backer around psychedelic drug development and adjacent neuropsychiatry.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Company-Led Drug Development & Commercialization
Portfolio Signals
Delix Therapeutics
Series A · $70M round · Sep 27, 2021
Prime Movers Lab
Prime Movers Lab is a venture capital firm and family of funds focused on breakthrough scientific startups, with an emphasis on technically ambitious companies in areas like energy, transportation, infrastructure, manufacturing, human augmentation, and agriculture. Public filings and firm materials place its business in Jackson/Teton Village, Wyoming, in the United States. In the psychedelic ecosystem, Prime Movers Lab is relevant because it has explicitly backed psychedelic medicine and related neuroplasticity work, including Gilgamesh and a participation in Beckley Psytech’s most recent round through an SPV. Its public portfolio and ideas pages also show ongoing attention to psychedelics alongside adjacent neuroscience and biotech themes.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Company-Led Drug Development & Commercialization
Portfolio Signals
Gilgamesh Pharma
private placement
Beckley Psytech
series round via SPV · undisclosed
Psych Capital
Psych Capital is a public-market psychedelic investor and media platform built around the medical psychedelics sector. Public filings describe it as the first pure-play psychedelic company to list in London, with an early-stage investment strategy focused on building and growing businesses within psychedelic healthcare. It matters in the psychedelic ecosystem because it combines market coverage, events, and capital allocation around the sector, rather than operating as a generalist fund. Public filings show it has invested in Awakn Life Sciences and has explored further early-stage opportunities in medical psychedelics.
View Profile
Investor Category
Venture Capital
HQ
HQ: United Kingdom
SeedSeries A/BGrowth / Late Stage
Company-Led Drug Development & Commercialization
Portfolio Signals
Awakn Life Sciences
private investment · £300,000 · Jun 11, 2021
PsyMed Ventures
PsyMed Ventures is a venture capital fund focused on brain and mental health innovation, with an explicit emphasis on psychedelic medicine, neurotechnology, precision psychiatry, digital therapeutics, and related frontier technologies. Public sources describe it as San Francisco-based and founded in 2020. In the psychedelic ecosystem, PsyMed Ventures appears as an early-stage backer of companies working across clinical infrastructure, therapeutics, and mental health platforms. Its publicly listed portfolio includes Journey Clinical, Maya Health, Mindstate Design Labs, and Reset Pharma, which places it across both psychedelic care delivery and drug-development-adjacent models.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/B
Company-Led Drug Development & CommercializationPractitioner-Led Care OrganizationsTechnology, Data, & Software Platforms
Portfolio Signals
Journey Clinical
Portfolio partner
Maya Health
Portfolio partner
QC Ventures
QC Ventures is the venture capital investment brand of Q·ADVISERS and describes itself as a deal-by-deal principal investor rather than a traditional fund. Its website says it has historically invested from Seed to Series A and beyond, with the ability to follow on at later stages. QC Ventures has publicly written about psychedelic and adjacent life-science opportunities, including atai Life Sciences and COMPASS Pathways. The firm says it has backed companies with scalable business models across industries and geographies, while also highlighting its role in the psychedelics value chain from research to clinics. The firm is associated with Vienna on its website and is tied to Q·CAPITAL VENTURES GmbH in the site footer, which points to an Austria-based operating presence. Its public materials also describe an active network of co-investors and strategic partners.
View Profile
Investor Category
Venture Capital
HQ
HQ: Austria
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
atai Life Sciences
convertible round · $24M round · Apr 30, 2020
RA Capital Management
RA Capital Management is a large, multi-stage healthcare and life-sciences investment manager that funds and builds companies across a wide development spectrum. Its public materials stress evidence-based investing, company formation, and deep scientific diligence. For psychedelic medicine, RA Capital is relevant because it publicly lists Delix Therapeutics in its venture portfolio and Delix financing materials identify RA as a lead investor in the company's Series A. This is a strong psychedelic-adjacent record, while RA remains best framed as a broad life-sciences investor.
View Profile
Investor Category
Institutional Investors
HQ
HQ: United States
SeedSeries A/BGrowth / Late StagePublic MarketsMulti-StageNonprofit / grant-backed
Company-Led Drug Development & Commercialization
Portfolio Signals
Delix Therapeutics
Series A · $70 million · Sep 27, 2021
re.Mind
re.Mind Capital is a venture capital fund focused on mental health, brain health, and human flourishing, with a public website that lists its office in London and a Maltese company footer. Its site also describes it as a leading early-stage investor, and its legal pages identify re.Mind Capital Limited with an address in Sliema, Malta. In the psychedelic ecosystem, re.Mind matters because its public stories and investment context show activity across brain-computer interfaces and psychedelic-related therapeutics, including a featured story about Delix and a story page highlighting Small Pharma. Public references also describe the fund as part of Christian Angermayer’s Apeiron ecosystem and as an investor in psychedelic medicine alongside other neurotechnology and mental health themes.
View Profile
Investor Category
Venture Capital
HQ
HQ: Malta
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
Public portfolio context is limited.
Route 66 Ventures
Route 66 Ventures is a private venture capital investor that backs early-stage companies, with a stated focus on digital health and wellness as well as financial technology. Public company information places the firm in Alexandria, Virginia, United States. In the psychedelic ecosystem, Route 66 Ventures is relevant because its portfolio includes Sensorium Therapeutics, a biotechnology company developing nature-inspired psychoactive medicines for mental health. That makes the firm a visible investor in adjacent mental health drug development rather than a generalist consumer or software fund.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
Public portfolio context is limited.
RTW Venture Fund
RTW Venture Fund is a life sciences investment vehicle associated with RTW Investments, LP, which describes itself as a New York-based, global, full life-cycle investment firm focused on biopharmaceutical and medical technology innovation. Public RTW materials describe the platform as investing across the lifecycle, including venture, crossover, and public company investments. In the psychedelic ecosystem, RTW Venture Fund appears relevant mainly through adjacent neuropsychiatric and drug-development investing rather than a stated psychedelic-only mandate. RTW has also backed Amani Therapeutics, a company developing a therapy for serious neuropsychiatric disorders, which suggests interest in central nervous system programs that may overlap with psychedelic-adjacent clinical and translational work.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
Public portfolio context is limited.
Subversive Capital
Subversive Capital is a New York-based investment firm that operates across venture investing, public markets, activism, whistleblower financing, and ETFs. Public filings and the firm’s site describe it as active in early- and late-stage investments, with a focus on companies that operate in highly regulated or category-defining sectors. In the psychedelic ecosystem, Subversive is relevant because it has participated in atai Life Sciences financing rounds, including atai’s Series D in 2021. Its public positioning and board-level involvement with atai suggest a broader interest in regulated mental health and psychedelic-adjacent opportunities.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
Public portfolio context is limited.
Tabula Rasa Ventures
Tabula Rasa Ventures is a venture capital firm focused on investing in health-related companies, including drug development, healthcare infrastructure, and digital therapeutics. Its website and profiles describe it as an early-stage investor with activity from pre-seed and seed through growth-stage financing. Public-facing sources point to New York, New York, in the United States as its base of operations. It matters in the psychedelic ecosystem because Tabula Rasa has explicitly backed psychedelic companies and frames part of its work around psychedelic and psychedelic-adjacent entrepreneurship. Its portfolio page includes Lykos Therapeutics and Natural MedTech, both tied to psychedelic drug development and research, and the firm has also described itself as supporting a psychedelic business incubator.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
Lykos Therapeutics
Series A · $100M · Sep 29, 2023
Natural MedTech
Jan 1, 2021
The Conscious Fund
The Conscious Fund is a venture capital adviser and fund focused on early-stage psychedelic medicine and adjacent therapeutic innovation. Its public materials describe the firm as backing pioneers of psychedelic medicine, state of mind, and advanced therapeutics, and an SEC Form ADV identifies its legal entity as TCF Management LLC. The firm’s relevance in the psychedelic ecosystem comes from its explicit specialization in psychedelic medicine and its role as an early-stage investor in the sector. Public materials also indicate a global investment lens, with the firm describing itself as investing in global early-stage ventures in psychedelic medicine.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
Mindleap Health
Seed · $11.5M · Feb 1, 2022
Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners (VHCP) is Venrock’s later-stage healthcare investing program, focused on publicly held and late-stage private healthcare companies. Venrock is a venture capital firm founded in 1969, and public Venrock materials describe VHCP as a public and cross-over biotech fund. The firm’s team is based across Palo Alto and New York, with Venrock also operating in Boston. VHCP matters to the psychedelic ecosystem mainly as a broader life-sciences and drug-development investor rather than a dedicated psychedelics fund. Venrock’s public materials emphasize biotechnology, pharmaceuticals, and crossover/public healthcare investing, with team members who have experience across the full drug-development arc and in neurodegenerative disease programs.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Portfolio Signals
Public portfolio context is limited.
Vine Ventures
Vine Ventures is an early-stage venture capital firm that describes its work as focused on health and wellness, with a particular interest in psychedelics, mental health, consciousness, and related life sciences themes. The firm says it was started in 2020 and operates with a presence in New York City and Tel Aviv. In the psychedelic ecosystem, Vine has positioned itself as a backer of companies and initiatives tied to psychedelic therapies and adjacent mental health models. Its public materials say it has led a large financing vehicle for MAPS to help bring MDMA to market for PTSD and that its team publishes and hosts content around psychedelic science and distribution.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Community Networks & OutreachEducational Platforms & ResourcesMedia & Communication
Portfolio Signals
MAPS
SPV / private financing · almost $45M
What If Ventures
What If Ventures is a venture capital firm founded in 2020 and based in Frisco, Texas, United States. It invests from seed through pre-IPO and describes itself as focused on health, freedom, mental health, and disruptive healthcare, with some portfolio exposure to psychedelic and adjacent mental health companies. In the psychedelic ecosystem, What If Ventures matters because its portfolio includes companies such as Atai Life Sciences, Beckley Psytech, and 2A Biosciences, all of which are publicly associated with psychedelic medicine or psychedelic-adjacent drug development. The firm’s public portfolio and team pages show continued interest in mental health innovation, addiction, biomarkers, and psychiatric drug development.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Company-Led Drug Development & Commercialization
Portfolio Signals
atai Life Sciences
Beckley Psytech
Y Combinator
Y Combinator is a startup accelerator and venture investor founded in 2005. It is based in San Francisco, California, and also lists Mountain View, California as a location on its public company profile. YC funds companies across software and biotech, and says it is especially comfortable funding life science projects at their earliest stage. In its current public biotech and drug-discovery materials, YC highlights work ranging from therapeutics to mental health and psychedelic medicine-adjacent companies.
View Profile
Investor Category
Venture Capital
HQ
HQ: United States
SeedSeries A/BGrowth / Late Stage
Company-Led Drug Development & CommercializationTechnology, Data, & Software Platforms
Portfolio Signals
Osmind
Mindstate Design Labs

Investor Landscape

Explore investor stakeholders by type, funding stage, and sector focus across the psychedelic ecosystem.

Investor Types

Institutional Investors1

Venture Capital44

Stage Focus

Seed42Series A/B42Growth / Late Stage38Multi-Stage3Pre-Seed2Public Markets1

Focus Areas

Drug Development44Clinical Infrastructure6Digital Therapeutics & Platforms6Manufacturing & Supply Chain1Provider Network Expansion1

Venture Capital

Company Context

Investor Landscape

Investor Types

Stage Focus

Focus Areas

Company

Product

Legal

Company Context